October 9th 2024
CNTN1 and NRXN3 clearly differentiated severe and milder forms of spinal muscular atrophy (SMA).
The introduction of 3 FDA-approved therapies for spinal muscular atrophy is enabling clinicians to treat the disease completely different from how it was handled in the past.
Multidisciplinary Care Emphasized for Pregnant Women With SMA